NRX Pharmaceuticals (NRXP) Payables (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Payables of $13.2 million for Q1 2026, down 7.05% year-over-year from $14.2 million in Q1 2025, and down 20.57% quarter-over-quarter from $16.6 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Payables (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Payables for 10 consecutive years, with $13.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 7.05% year-over-year to $13.2 million; the TTM figure through Mar 2026 stood at $13.2 million (down 7.05% YoY), while the FY2025 annual figure was $16.6 million, up 69.66% from the prior year.
- Payables retreated to $13.2 million in Q1 2026 per NRXP's latest filing, from $16.6 million in the prior quarter.
- Across five years, Payables topped out at $16.6 million in Q4 2025 and bottomed at $2.1 million in Q4 2022.
- Historically, Payables has averaged $8.7 million across 5 years, with a median of $6.8 million in 2024.
- Annual changes were most pronounced in 2022 — Payables plunged 89.36% — and 2023, when it surged 516.01%.
- NRX Pharmaceuticals' Payables stood at $2.1 million in 2022, then jumped by 120.02% to $4.6 million in 2023, then surged by 110.13% to $9.8 million in 2024, then soared by 69.66% to $16.6 million in 2025, then fell by 20.57% to $13.2 million in 2026.
- Business Quant data shows NRXP's Payables at $13.2 million in Q1 2026, $16.6 million in Q4 2025, and $14.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 35.57 Mn |
| 10 | NRX Pharmaceuticals | 133.09 Mn | 106.39 Mn | 426,000.00 | 21.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.17 Mn |
| Dec 31, 2025 | 16.57 Mn |
| Sep 30, 2025 | 14.17 Mn |
| Jun 30, 2025 | 13.48 Mn |
| Mar 31, 2025 | 14.16 Mn |
| Dec 31, 2024 | 9.77 Mn |
| Sep 30, 2024 | 6.77 Mn |
| Jun 30, 2024 | 5.02 Mn |
| Mar 31, 2024 | 6.29 Mn |
| Dec 31, 2023 | 4.65 Mn |
| Sep 30, 2023 | 13.70 Mn |
| Jun 30, 2023 | 2.24 Mn |
| Mar 31, 2023 | 15.97 Mn |
| Dec 31, 2022 | 2.11 Mn |
| Sep 30, 2022 | 2.22 Mn |
| Jun 30, 2022 | 3.10 Mn |
| Mar 31, 2022 | 4.81 Mn |
| Dec 31, 2021 | 3.98 Mn |
| Sep 30, 2021 | 6.82 Mn |
| Jun 30, 2021 | 29.11 Mn |